On this page
Nuvaxovid
COVID-19 Vaccine, Adjuvanted
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Nuvaxovid
Proper name
COVID-19 Vaccine, Adjuvanted
Licence type
351(a)
BLA number
125817
Applicant
Sanofi Vaccines US Inc.
Center
CBER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 5UG | Injection | Intramuscular | Pre-Filled Syringe | Rx | May 16, 2025 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |